AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22186855 — intervention group
Group type: EXPERIMENTAL
Intervention: First-born children with siblings
Number of subjects: 200
Study 22186855 — intervention group
Group type: COMPARATOR
Intervention: Children with siblings (not specified if first-born or later-born)
Number of subjects: 200
Study 19837909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet 30 mg twice daily, increasing to 50 mg twice daily during the 12-week titration if serum calcium levels were 10.3 mg/dl or higher
Number of subjects: 45
Study 19837909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 45
Study 16946029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine receptor antagonism with aminophylline (Aph)
Number of subjects: 19
Study 16946029 — intervention group
Group type: COMPARATOR
Intervention: Control (no aminophylline)
Number of subjects: 19
Study 14724146 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (HpE group)
Number of subjects: 104
Study 14724146 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole with placebo antibiotics (Hp+ group)
Number of subjects: 104
Study 11368990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary 1
Number of subjects: 0
Study 11368990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary 2
Number of subjects: 0
Study 11368990 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary 3
Number of subjects: 0
Study 11368990 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-in regimen
Number of subjects: 0
Study 9402119 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal tube placement
Number of subjects: 67
Study 9402119 — intervention group
Group type: COMPARATOR
Intervention: Standard management without tube placement
Number of subjects: 67
Study 7634265 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 7634265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2531457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarapid induction (Group II)
Number of subjects: 60
Study 2531457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarapid induction protected by fentanyl (Group III)
Number of subjects: 60
Study 2531457 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 60
Study 31780570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg every 3 weeks, typically for ≤12 months) combined with front-line chemotherapy (carboplatin/paclitaxel)
Number of subjects: 299
Study 31780570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg) with chemotherapy
Number of subjects: 299
Study 31780570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg)
Number of subjects: 299
Study 31780570 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 299
Study 30445875 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video on schizophrenia
Number of subjects: 260
Study 30445875 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 260
Study 25951945 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBLs
Number of subjects: 288
Study 25951945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 24267002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) plus anti-thymocyte globulin (ATG) for severe AA (SAA) patients
Number of subjects: 186
Study 24267002 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) alone for non-severe AA (NSAA) patients
Number of subjects: 186
Study 24267002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) plus anti-thymocyte globulin (ATG) for SAA patients
Number of subjects: 186
Study 24267002 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) alone for NSAA patients
Number of subjects: 186
Study 24267002 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG plus CsA or CsA alone
Number of subjects: 186
Study 21723703 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery (CAS)
Number of subjects: 208
Study 21723703 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA instrumentation
Number of subjects: 208
Study 18563416 — intervention group
Group type: EXPERIMENTAL
Intervention: CT findings associated with WOPN
Number of subjects: 73
Study 18563416 — intervention group
Group type: EXPERIMENTAL
Intervention: CT score of 2 or higher
Number of subjects: 73
Study 18563416 — intervention group
Group type: COMPARATOR
Intervention: Presence of pancreatic duct dilation
Number of subjects: 73
Study 17214260 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser stapedotomy
Number of subjects: 336
Study 17214260 — intervention group
Group type: COMPARATOR
Intervention: Microdrill stapedotomy
Number of subjects: 336
Study 17214260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (laser and microdrill)
Number of subjects: 336
Study 14727235 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT plus amifostine (300 mg/m(2) daily intravenous infusion)
Number of subjects: 73
Study 14727235 — intervention group
Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 73
Study 10741446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cholangiography (IOC) performed in 435 patients (87%)
Number of subjects: 500
Study 10741446 — intervention group
Group type: COMPARATOR
Intervention: Postoperative pancreatitis
Number of subjects: 500
Study 8638338 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 225
Study 8638338 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 225
Study 8638338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 225
Study 1852797 — intervention group
Group type: EXPERIMENTAL
Intervention: Training once every other week (n = 10)
Number of subjects: 56
Study 1852797 — intervention group
Group type: EXPERIMENTAL
Intervention: Training once per week (n = 12)
Number of subjects: 56
Study 1852797 — intervention group
Group type: EXPERIMENTAL
Intervention: Training twice per week (n = 12)
Number of subjects: 56
Study 1852797 — intervention group
Group type: EXPERIMENTAL
Intervention: Training three times per week (n = 7)
Number of subjects: 56
Study 1852797 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group (n = 15)
Number of subjects: 56
Study 6864403 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked human milk (BHM)
Number of subjects: 76
Study 6864403 — intervention group
Group type: COMPARATOR
Intervention: Protein‐mineral‐calorie‐enriched formula (Similac Special Care)
Number of subjects: 76
Study 6864403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 30862193 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR (4, 10, or 25 μg)
Number of subjects: 0
Study 30862193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28653345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bimagrumab 30 mg/kg
Number of subjects: 40
Study 28653345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26764182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive enteral nutrition plus methylprednisolone
Number of subjects: 136
Study 26764182 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition plus methylprednisolone (controls)
Number of subjects: 136
Study 26764182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (regardless of intervention)
Number of subjects: 136
Study 24432712 — intervention group
Group type: EXPERIMENTAL
Intervention: EXAcerbations of Chronic Pulmonary Disease Tool (EXACT)
Number of subjects: 1581
Study 22528280 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC)
Number of subjects: 47
Study 22528280 — intervention group
Group type: COMPARATOR
Intervention: Control (medical management)
Number of subjects: 47
Study 19914571 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical compression stocking (TED)
Number of subjects: 295
Study 19914571 — intervention group
Group type: COMPARATOR
Intervention: Elastic bandage
Number of subjects: 295
Study 17307412 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration before transfer to catheterization laboratory (27 patients)
Number of subjects: 59
Study 17307412 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration immediately before PPCI (32 patients)
Number of subjects: 59
Study 15011245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovaginal coil MR imaging at 1.5 T with T(1)‐ and T(2)‐weighted scans
Number of subjects: 53
Study 15011245 — intervention group
Group type: COMPARATOR
Intervention: Ex vivo analysis using MAS‐MR spectroscopy
Number of subjects: 53
Study 11685730 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and exisulind combination therapy
Number of subjects: 0
Study 9593960 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI during picture naming task for animals
Number of subjects: 12
Study 9593960 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI during picture naming task for furniture items
Number of subjects: 12
Study 9059766 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with a low-calorie diet and metformin 1,700 mg/day
Number of subjects: 82
Study 9059766 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 82
Study 2759222 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (Mx)
Number of subjects: 9
Study 2759222 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 9
Study 73014 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 100
Study 73014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30905926 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin combined group
Number of subjects: 80
Study 30905926 — intervention group
Group type: COMPARATOR
Intervention: Insulin group (Control)
Number of subjects: 80
Study 28854929 — intervention group
Group type: EXPERIMENTAL
Intervention: F-75 to RUTF transition
Number of subjects: 341
Study 28854929 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 341
Study 28854929 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of child
Number of subjects: 341
Study 28854929 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 341
Study 28854929 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver assessment of illness severity
Number of subjects: 341
Study 28854929 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF acceptance
Number of subjects: 341
Study 25822991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 40
Study 25822991 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40
Study 23512355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab for 16 weeks
Number of subjects: 14
Study 23512355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 14
Study 23512355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 22256635 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoroughfare Vessel theory acupuncture (Dazhu (BL 11), Shangjuxu (ST 37), Xiajuxu (ST 39), Neiguan (PC 6), Gongsun (SP 4))
Number of subjects: 78
Study 22256635 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (Fengchi (GB 20), Lianquan (CV 23), Tiantu (CV 22), Neiguan (PC 6), Zusanli (ST 36))
Number of subjects: 78
Study 18500521 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg twice per day, 4 days before and on the day of chemotherapy (cohort 2)
Number of subjects: 30
Study 18500521 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 16 mg twice per day, 4 days before and on the day of chemotherapy (cohort 3)
Number of subjects: 30
Study 18500521 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone (cohort 1)
Number of subjects: 30
Study 18500521 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of dexamethasone
Number of subjects: 30
Study 16702889 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose venlafaxine ER (mean dose = 309 mg/d)
Number of subjects: 232
Study 16702889 — intervention group
Group type: COMPARATOR
Intervention: Standard dose venlafaxine ER (mean dose = 148 mg/d)
Number of subjects: 232
Study 16702889 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose venlafaxine ER
Number of subjects: 232
Study 16702889 — intervention group
Group type: COMPARATOR
Intervention: Standard dose venlafaxine ER
Number of subjects: 232
Study 15373931 — intervention group
Group type: COMPARATOR
Intervention: bezafibrate
Number of subjects: 12
Study 15373931 — intervention group
Group type: COMPARATOR
Intervention: fenofibrate
Number of subjects: 12
Study 15373931 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 10884467 — intervention group
Group type: EXPERIMENTAL
Intervention: GRE‐EPI
Number of subjects: 198
Study 9288840 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART (54 Gy in 36 fractions over 12 days)
Number of subjects: 918
Study 9288840 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (66 Gy in 33 fractions over 6.5 weeks)
Number of subjects: 918
Study 9288840 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 918
Study 9288840 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 918
Study 8321736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 159
Study 8321736 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 159
Study 8321736 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups of ramipril and enalapril
Number of subjects: 159
Study 8321736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (all dosages)
Number of subjects: 159
Study 3759915 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral dose of oxazepam in capsule form
Number of subjects: 17
Study 3759915 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral dose of oxazepam in tablet form
Number of subjects: 17
Study 29933113 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction (D-RES; 15 kcal·kg LBM‐1·d‐1)
Number of subjects: 10
Study 27629738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime prophylaxis (Group I, n = 25)
Number of subjects: 50
Study 27629738 — intervention group
Group type: COMPARATOR
Intervention: No perioperative antibiotic therapy (Group II, n = 25)
Number of subjects: 50
Study 25013787 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-Y FBPJ
Number of subjects: 47
Study 25013787 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn closure
Number of subjects: 47
Study 22860693 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular hypotonic ORS (Na 60 mmol/L, glucose 78 mmol/L)
Number of subjects: 147
Study 22860693 — intervention group
Group type: COMPARATOR
Intervention: Apple-flavoured hypotonic ORS (same composition as regular ORS)
Number of subjects: 147
Study 22860693 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular hypotonic ORS
Number of subjects: 147
Study 22860693 — intervention group
Group type: COMPARATOR
Intervention: Apple-flavoured hypotonic ORS
Number of subjects: 147
Study 20815864 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale (SWLS)
Number of subjects: 243
Study 20815864 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Satisfaction Questionnaire (LISAT-9)
Number of subjects: 243
Study 20815864 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Well-Being Index (PWI)
Number of subjects: 243
Study 20815864 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-item World Health Organization Quality of Life Assessment (WHOQoL-5)
Number of subjects: 243
Study 20815864 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc procedures applied to WHOQoL-5 and PWI
Number of subjects: 243
Study 18822473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational fusafungine
Number of subjects: 100
Study 18822473 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (per os or parenteral)
Number of subjects: 100
Study 15792513 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (HYPO) (32-33 degrees C)
Number of subjects: 48
Study 15792513 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (NORM) (36.5-37.5 degrees C)
Number of subjects: 48
Study 12500983 — intervention group
Group type: EXPERIMENTAL
Intervention: MILK
Number of subjects: 9
Study 12500983 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 9
Study 12500983 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 9
Study 10087687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 107
Study 10087687 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic behavioral family therapy
Number of subjects: 107
Study 10087687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirective supportive therapy
Number of subjects: 107
Study 10087687 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study 7500603 — intervention group
Group type: EXPERIMENTAL
Intervention: Microagglutination test
Number of subjects: 30
Study 1973583 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (4 mg) intravenously injected
Number of subjects: 0
Study 1973583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 304522 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol syrup
Number of subjects: 144
Study 304522 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol suppositories
Number of subjects: 144
Study 304522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paracetamol with doxylaminsuccinate
Number of subjects: 144
Study 31023125 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 45 years
Number of subjects: 4072
Study 31023125 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 65 years
Number of subjects: 4072
Study 28134753 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Beamforming (CB)
Number of subjects: 0
Study 28134753 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed requirements for CB
Number of subjects: 0
Study 25701046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyric analysis intervention using 'Hurt' or 'How to Save a Life'
Number of subjects: 104
Study 25701046 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 104
Study 23623339 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg/kg ketamine
Number of subjects: 60
Study 23623339 — intervention group
Group type: COMPARATOR
Intervention: 4 mcg/kg dexmedetomidine
Number of subjects: 60
Study 21791356 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units of onabotulinum toxin A
Number of subjects: 134
Study 21791356 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 units of onabotulinum toxin A
Number of subjects: 134
Study 19154492 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive management (NIM) with immediate empirical antibiotic treatment (n = 34)
Number of subjects: 68
Study 19154492 — intervention group
Group type: COMPARATOR
Intervention: Invasive management (IM) based on protected brush sampling of specimens (n = 34)
Number of subjects: 68
Study 17451425 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/20 mg
Number of subjects: 661
Study 17451425 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/40 mg
Number of subjects: 661
Study 17451425 — intervention group
Group type: COMPARATOR
Intervention: ATV 20 mg
Number of subjects: 661
Study 17451425 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE/SIMVA 10/20 mg, EZE/SIMVA 10/40 mg, ATV 20 mg
Number of subjects: 661
Study 15070662 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG (Fludarabine + ARA-C + G-CSF)
Number of subjects: 134
Study 15070662 — intervention group
Group type: COMPARATOR
Intervention: AG (ARA-C + G-CSF)
Number of subjects: 134
Study 11419672 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminopenicillins at the correct dose
Number of subjects: 0
Study 11419672 — intervention group
Group type: COMPARATOR
Intervention: Macrolides and fluoroquinolones
Number of subjects: 0
Study 9431610 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose traction
Number of subjects: 151
Study 9431610 — intervention group
Group type: COMPARATOR
Intervention: Sham (low-dose) traction
Number of subjects: 151
Study 8214532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% (150 mg)
Number of subjects: 44
Study 8214532 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.75% (112.5 mg)
Number of subjects: 44
Study 3658314 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 20
Study 3658314 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 20
Study 31280941 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified External Rotation Method (MERM)
Number of subjects: 62
Study 31280941 — intervention group
Group type: COMPARATOR
Intervention: External Rotation Method (ERM)
Number of subjects: 62
Study 29565666 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study 29565666 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system (in male participants)
Number of subjects: 4407
Study 29565666 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 4407
Study 27580443 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSIB (Palmar Subcutaneous Single Injection Block)
Number of subjects: 190
Study 27580443 — intervention group
Group type: COMPARATOR
Intervention: DTIB (Dorsal 2 Injection Block)
Number of subjects: 190
Study 27580443 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSIB
Number of subjects: 190
Study 27580443 — intervention group
Group type: COMPARATOR
Intervention: DTIB
Number of subjects: 190